Entera Bio (ENTX) Q1 2026 earnings summary

Executive summary

• Focused on developing oral peptide therapies for chronic conditions, with lead candidates EB613 (osteoporosis), EB612 (hypoparathyroidism), and EB618 (obesity/metabolic disorders).

• Advanced EB613 to Phase 3 protocol submission and completed a critical Phase 1 bridging study; expanded OPKO collaboration for EB612 and EB618 programs, with IND filing for EB612 planned for late 2026.

• Submitted new data for EB613, EB612, and EB618 to major endocrinology conferences.

• Secured direct investment led by BVF Partners L.P. to accelerate pivotal studies and strengthen working capital.

• No product sales revenue; operations funded by equity offerings, grants, and collaborations.

Financial highlights

• Net loss for Q1 2026 was $3.5 million ($0.07 per share), up from $2.6 million ($0.06 per share) in Q1 2025, driven by higher R&D expenses.

• Research and development expenses rose to $2.3 million from $1.1 million year-over-year, mainly due to increased clinical activity and collaboration costs.

• General and administrative expenses decreased slightly to $1.3 million from $1.4 million.

• Cash and cash equivalents plus restricted cash totaled $11.9 million as of March 31, 2026, rising to $20.4 million by May 8, 2026, after a private placement and restricted cash for OPKO collaboration.

• April 2026 private placement raised $10 million in gross proceeds, with $7.8 million restricted for OPKO collaboration.

Outlook and guidance

• Existing cash resources expected to fund operations through Q1 2027, including Phase 3 preparation for EB613.

• Additional funding required to commence and complete the EB613 Phase 3 study; delays possible if funding is not secured.

• Ongoing evaluation of financing alternatives and strategic collaborations.

• IND filing for EB612 anticipated in late 2026.